Login / Signup

The addition of lopinavir-ritonavir to carfilzomib-based triplets can induce meaningful clinical response in carfilzomib-refractory myeloma patients: a single-center experience.

Rory BennettHenry ChanRoss HendersonEileen MerrimanMerit HannaAnna Elinder-CamburnDavid Simpson
Published in: Leukemia & lymphoma (2022)
Keyphrases
  • multiple myeloma
  • newly diagnosed
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • peritoneal dialysis
  • prognostic factors
  • antiretroviral therapy
  • patient reported